Navigation Links
New tuberculosis drug trial begins in South Africa
Date:12/11/2012

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

The study is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health. It is being conducted by the NIAID-supported Tuberculosis Research Unit of Case Western University School of Medicine of Cleveland, Ohio, and is taking place in Cape Town, South Africa with TASK Applied Science, a South African clinical research group that specializes in TB trials.

TB, which causes 1.4 million deaths per year, is the leading infectious cause of death among people with HIV/AIDS . The emergence of drug-resistant TB and the lack of new drugs to fight the disease effectively are major challenges to controlling this serious global public health concern.

"New medications are greatly needed to improve and shorten the treatment of TB in high-burden countries," says John L. Johnson, MD, professor of medicine in the Division of Infectious Diseases and HIV Medicine at Case Western Reserve School of Medicine and staff physician at University Hospitals Case Medicine Center. "This trial is the first step in testing this new potential drug in humans with active TB."

Johnson is an internationally-renowned investigator with the Tuberculosis Research Unit at Case Western Reserve, an inter-disciplinary, inter-national consortium of investigators and institutions with expertise in epidemiology, microbiology, immunity, prevention and treatment of TB. Supported by the NIH, the Tuberculosis Research Unit is the only NIH-funded research unit in the US focused on human TB.

AZD5847 has been developed by AstraZeneca and belongs to a class of antibiotics that are active against Gram-positi
'/>"/>

Contact: Jessica Studeny
jessica.studeny@case.edu
216-368-4692
Case Western Reserve University
Source:Eurekalert

Page: 1 2

Related biology news :

1. Biosignatures distinguish between tuberculosis and sarcoidosis
2. Targeting tuberculosis hotspots could have widespread benefit
3. MIT-designed cooler preserves tuberculosis drugs, records doses
4. Research on improvements in diagnosing and treating tuberculosis
5. Millions of diabetics could die of tuberculosis
6. New approach of resistant tuberculosis
7. Iowa State, Ames Lab researchers study the structure of drug resistance in tuberculosis
8. High doses of Vitamin D help tuberculosis patients recover more quickly
9. Scientists reveal how natural antibiotic kills tuberculosis bacterium
10. Notre Dame research could provide new insights into tuberculosis and other diseases
11. Missing link discovered in the defence mechanism of the tuberculosis pathogen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Hand Geometry - Global Strategic Business Report" report to ... for Hand Geometry in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... America . Annual estimates and forecasts are ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... researchers from 80 countries, the world,s scientists as well as ... Life, which provides the first in-depth look at the more ... of Marine Life initiative, started in 2000, is the result of ... of more than 540 expeditions and 9,000 days at sea, plus ...
... The new center is a continuum for the Center ... VTT in Finland. The center in So Paulo aims to ... American market. Important focus areas will be biomass, bioethanol, pulp ... R&D center in So Paulo is the fourth part in ...
... , Washington, D.C. (October 5, 2010) -- A prototype ... to non-invasively test drugs for their ability to kill ... The new device is built upon microfluidics -- a ... of fluids at the sub-millimeter scale -- and is ...
Cached Biology News:San Diego Supercomputer Center participates in first 'Census of Marine Life' 2Kemira and VTT to open a joint R&D center in Brazil 2Anti-tumor drugs tested by microfluidic device 2
(Date:3/29/2015)... Texas , March 29, 2015 /PRNewswire/ ... presentation of important study data showing the ... in 1,599 gynecologic cancer samples. Using Caris ... profiling service, researchers identified expression of programmed ... cancers independent of histology while its ligand ...
(Date:3/27/2015)... March 27, 2015 Earlier this year, ... promotion of hair regrowth in adult men and women ... or Norwood Hamilton classifications of IIa-V and Fitzpatrick Classification ... plagued by products that over-promise and under-deliver, FDA Clearance ... faith and confidence among more than 80 million men ...
(Date:3/27/2015)... 27. März 2015  Peter Walter wurde ... Science für seine bahnbrechende Arbeit ausgewählt, die ... transportiert werden, sowie für die Entschlüsselung der ... auf Stress nutzen, der mit der Ansammlung ... Professor für Biochemie an der University of ...
(Date:3/27/2015)... 2015   SurePure, Inc . (OTCQB: SURP), ... that the Company has completed the verification process ... SurePure ("SURP") securities on OTCQB, an electronic quote ... development stage companies. On March 26, ... requirements designed to improve marketplace integrity and enhance ...
Breaking Biology Technology:Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2
... , , LA JOLLA, Calif., ... molecular diagnostics for the early detection of disease plus additional ... of a feasibility study using DermTech,s advanced EGIR(TM) technology to ... The two companies will now move forward with a proof-of-concept ...
... , CALGARY, July 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ... that a poster presentation by Dr. Jacqueline Parker et ... in Combination with Temozolomide and Low Dose Irradiation in ... Therapy Alone" was made yesterday at the 28th American ...
... PRINCETON, N.J., July 15 BioWa, Inc. announced today that ... Darmstadt, Germany, providing the global healthcare and chemicals company with ... and commercialization of their antibody therapies with enhanced antibody-dependent cellular ... "We are extremely pleased about our partnership with Merck KGaA, ...
Cached Biology Technology:DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 2DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology 3Oncolytics Biotech(R) Inc. Research Collaborators Present Glioma Reovirus Research at ASV Annual Meeting 2BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2
... large numbers of samples may be carried out ... which requires minimum operator attention. System control ... and interface CE 4900. The elegant, powerful ... Windows XP and Windows 98 and 2000., The ...
... Highly nutritious peptone, used ... production of bacterial toxins, ... of bacteria with high ... Haemophilus, Neisseria, Pasteurella, Salmonella ...
... Human Raji cells were cultured in RPMI 1640 ... the log phase of growth. In order ... cells were fixed in acetone-methanol. The cells ... coated slide, with each wells surface specifically treated ...
... Human 293 cells were cultured in Minimum ... harvested at the log phase of growth. ... native forms, cells were fixed in acetone-methanol. ... mm) adhesive coated slide, with each wells surface ...
Biology Products: